vs
Side-by-side financial comparison of BIOHARVEST SCIENCES INC. (BHST) and Paranovus Entertainment Technology Ltd. (PAVS). Click either name above to swap in a different company.
Paranovus Entertainment Technology Ltd. is the larger business by last-quarter revenue ($12.4M vs $8.4M, roughly 1.5× BIOHARVEST SCIENCES INC.).
BioHarvest Sciences Inc. is a biotechnology firm that develops and produces sustainable, high-purity plant-derived bioactive ingredients. It serves the nutraceutical, cosmetics, and pharmaceutical sectors, leveraging proprietary cell cultivation technology to create efficacious natural products without large-scale agricultural farming.
BHST vs PAVS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $12.4M |
| Net Profit | — | $-681.0K |
| Gross Margin | 60.3% | 20.0% |
| Operating Margin | — | -5.1% |
| Net Margin | — | -5.5% |
| Revenue YoY | — | 18033.4% |
| Net Profit YoY | — | 61.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $8.4M | $12.4M | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $7.7M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $6.0M | — | ||
| Q3 23 | — | $0 |
| Q3 25 | — | $-681.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $8.2M |
| Q3 25 | 60.3% | 20.0% | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 58.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | — | -5.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $5.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $23.6M |
| Total Assets | — | $37.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $1.0M |
| Q3 25 | — | $23.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $10.7M |
| Q3 25 | — | $37.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $11.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-159.3K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-159.3K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $-13.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | -1.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
